Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 6/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20148617 | 0.90 | RET (0.42) | RETALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL22811940 | 0.86 | RET (0.46) | RETALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL22030850 | 0.85 | RET (0.46) | RETALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL23126260 | 0.82 | RET (0.43) | RETALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL20071290 | 0.82 | RET (0.42) | RETALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL20160504 | 0.82 | RET (0.46) | RETALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL20148618 | 0.74 | ALDH1A1 (0.40) | RETALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL20152348 | 0.73 | RET (0.45) | RETALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL20071289 | 0.73 | DPP4 (0.41) | RETALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL20069727 | 0.72 | RET (0.44) | RETALDH1A1CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10555944-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190183886-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10555944-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | RET 1/4885ALDH1A1 2868/4885CYP1A2 3812/4885 |
| US-20190183886-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | RET 1/4885ALDH1A1 2868/4885CYP1A2 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.